IQVIA (NYSE:IQV) Price Target Cut to $279.00

IQVIA (NYSE:IQV) had its target price cut by JPMorgan Chase & Co. from $288.00 to $279.00 in a research report report published on Wednesday morning, Benzinga reports. They currently have an overweight rating on the medical research company’s stock.

Several other brokerages have also recently issued reports on IQV. Robert W. Baird boosted their price target on shares of IQVIA from $251.00 to $256.00 and gave the company a “neutral” rating in a research report on Friday, September 20th. Jefferies Financial Group lowered IQVIA from a “buy” rating to a “hold” rating and decreased their target price for the stock from $266.00 to $242.00 in a research report on Wednesday, July 24th. Redburn Atlantic assumed coverage on IQVIA in a research report on Monday, October 14th. They set a “buy” rating and a $276.00 price target on the stock. Argus upgraded IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. Finally, StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a research report on Tuesday, October 22nd. Five equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and an average target price of $267.27.

IQVIA Stock Performance

Shares of IQV stock opened at $214.63 on Wednesday. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 1.80. The stock has a fifty day moving average of $237.63 and a 200 day moving average of $230.60. The firm has a market capitalization of $39.11 billion, a price-to-earnings ratio of 29.32, a PEG ratio of 2.22 and a beta of 1.49. IQVIA has a 52 week low of $167.42 and a 52 week high of $261.73.

Insider Activity

In other news, insider Eric Sherbet sold 1,300 shares of the firm’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the transaction, the insider now directly owns 19,536 shares in the company, valued at $4,812,302.88. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.60% of the company’s stock.

Institutional Investors Weigh In On IQVIA

Several large investors have recently bought and sold shares of the business. First Trust Direct Indexing L.P. increased its holdings in IQVIA by 19.9% in the 3rd quarter. First Trust Direct Indexing L.P. now owns 10,825 shares of the medical research company’s stock worth $2,565,000 after buying an additional 1,798 shares in the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA increased its holdings in IQVIA by 132.4% in the 3rd quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 15,210 shares of the medical research company’s stock worth $3,604,000 after buying an additional 8,665 shares in the last quarter. Fortitude Family Office LLC increased its holdings in IQVIA by 2.9% in the 3rd quarter. Fortitude Family Office LLC now owns 1,977 shares of the medical research company’s stock worth $468,000 after buying an additional 56 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in IQVIA by 4,066.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,500 shares of the medical research company’s stock worth $829,000 after buying an additional 3,416 shares in the last quarter. Finally, Boston Financial Mangement LLC increased its holdings in IQVIA by 4.5% in the 3rd quarter. Boston Financial Mangement LLC now owns 7,644 shares of the medical research company’s stock worth $1,811,000 after buying an additional 327 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.